What is citicoline?

Citicoline (CDP-choline) is a compound your body makes on its own and that is also sold as a dietary supplement in the United States. It supplies choline, a nutrient used to build the membranes around brain cells. You may see it under several names: citicoline, CDP-choline, and the brand name Cognizin. These are all the same compound, and Cognizin is simply a branded form of it.

One important fact up front: citicoline is a dietary supplement in the US, not an FDA-approved drug. That means it has not been approved to treat, cure, or prevent any disease. Some health claims you will see online go well beyond what the research shows. For example, the largest stroke trial ever run on citicoline (about 2,300 people, published in *The Lancet* in 2012) found it did not improve 90-day recovery compared with placebo. Earlier, smaller studies had suggested benefit, but the big trial did not confirm them.

A stroke emergency note: If you or someone near you shows signs of a stroke, face drooping, arm weakness, slurred speech, call 911 immediately. Do not take citicoline or any supplement hoping it will help. Minutes matter, and only emergency medical care can limit brain damage.

This page covers what citicoline is, how it is named, and what is known about its safety. For a full review of what it may or may not help, see our evidence review. You can also browse the main citicoline hub or the supplements companion.

Evidence at a glance

Note: this is a fundamentals page about what the compound *is*, so the table focuses on naming, safety, and regulatory status rather than the full disease-by-disease record. That record lives at /evidence/.

The name problem: citicoline, CDP-choline, and Cognizin

The single most confusing thing about citicoline is that it goes by several names. Citicoline and CDP-choline refer to exactly the same molecule. The long chemical name is cytidine diphosphate-choline. Some supplement labels say citicoline; others say CDP-choline. There is no difference in what you are buying.

Cognizin is different only in that it is a brand name. It is a patented, branded form of citicoline made by one company and licensed to many supplement makers. If a label says "Cognizin citicoline," the active ingredient is still citicoline. We explain the naming history in more detail on our page about citicoline versus CDP-choline and on our Cognizin brand page.

Why does this matter? Because research findings get attached to one name and marketing claims to another. When you read a study, check which compound it actually used. When you read a supplement label, check whether the product lists plain citicoline or the branded form, the dose and the evidence base may differ.

What the body does with it

Citicoline breaks down into choline and cytidine once you swallow it. Choline is an essential nutrient. Your brain uses it to make acetylcholine, a signalling chemical involved in memory and attention, and to build phospholipids, the fatty layers that form cell membranes.

The proposed mechanism, that citicoline may support membrane phospholipid synthesis, is real basic science, but it is important to be honest about its limits. Mechanism studies and animal work are the lowest tiers of evidence. Calling citicoline "neuroprotective" based on lab findings is a leap, because the large human trials that would test that idea, like the stroke and traumatic brain injury trials, did not show the hoped-for benefit. A plausible mechanism is a starting point, not a result.

Why the stroke trial matters for every claim

The ICTUS trial (Dávalos and colleagues, *The Lancet*, 2012) enrolled about 2,300 people with acute stroke and gave them citicoline or placebo. At 90 days, recovery was no better in the citicoline group. Earlier meta-analyses of smaller stroke trials had suggested benefit, but those findings were not confirmed when the treatment was tested at scale.

This pattern, encouraging small studies followed by a negative large trial, is common in medicine, and it is why we rank evidence by tier. A similar result appeared in traumatic brain injury: the COBRIT trial (Zafonte, *JAMA*, 2012) found no improvement in functional or cognitive outcomes versus placebo. We mention these here not to give the full benefit record, which you can find at /evidence/, but because any honest answer to "what is citicoline?" has to include what the biggest and best trials found.

Safety, dosing ranges, and interactions

In clinical trials, citicoline at doses from 250 to 2,000 mg per day was generally well tolerated. The most common side effects were mild: stomach upset, headache, and insomnia. Serious harms were not a signal in the trial data.

Two cautions deserve attention. First, there is a lack of safety data in pregnancy and breastfeeding, so use in those situations is not established. Second, citicoline may enhance the effects of levodopa, a Parkinson's disease medication. If you take levodopa or have Parkinson's, involve your neurologist before adding citicoline. Beyond that, we do not give personal dosing advice; that is a conversation for your own clinician.

Expert insight

When readers ask me "what is citicoline?", I start with the naming: citicoline and CDP-choline are one compound, and Cognizin is a branded form of it, so label confusion is the first thing to clear up. I then tell them it is a dietary supplement in the United States, not an FDA-approved drug, and no claim on a bottle has been vetted the way a drug claim would be. On the evidence, I am honest about the pattern: smaller stroke studies suggested benefit, but the large ICTUS trial found no improvement in 90-day recovery, and the COBRIT trial in brain injury was also negative. There is modest, lower-quality evidence in chronic cerebrovascular cognitive decline, and small industry-funded studies in attention. Safety at studied doses looks reasonable, but pregnancy and breastfeeding data are lacking, and people on levodopa should speak with their neurologist. My bottom line is that citicoline is a well-defined compound with a mixed evidence record, and readers deserve to see the whole record rather than a highlight reel.

Questions readers ask

Is citicoline the same as CDP-choline?

Yes. They are two names for the same compound. Labels and studies use both terms interchangeably. See our naming page for details.

Is Cognizin a different ingredient?

No. Cognizin is a brand name for citicoline. The active compound is identical to plain citicoline. Our Cognizin page explains the branding.

Is citicoline FDA-approved?

No. In the United States it is sold as a dietary supplement. The FDA has not approved it to treat, cure, or prevent any disease.

Does citicoline help with stroke recovery?

The largest and best trial, ICTUS, found no improvement in 90-day recovery versus placebo. Earlier analyses suggested benefit but were not confirmed. If you suspect a stroke, call 911, do not rely on any supplement.

Does citicoline treat ADHD?

There is no good evidence that it does. Adequate ADHD trials have not been done.

Is citicoline safe?

In trials at 250, 2,000 mg per day it was generally well tolerated, with mild stomach upset, headache, and insomnia as the main side effects. Safety in pregnancy and breastfeeding is unknown.

Can I take citicoline with levodopa?

Citicoline may enhance levodopa's effects. If you have Parkinson's disease and take levodopa, talk with your neurologist first.

Where can I see the full evidence on benefits?

Our evidence review walks through every major claim, trial by trial, with quality tiers. You can also start from the citicoline hub or the supplements companion.

Sources

This article draws on the following studies and reviews: the ICTUS trial (Dávalos and colleagues, *The Lancet*, 2012) on acute stroke; earlier stroke meta-analyses suggesting benefit; the COBRIT trial (Zafonte and colleagues, *JAMA*, 2012) on traumatic brain injury; the Cochrane review by Fioravanti and Yanagi on chronic cerebrovascular cognitive decline; the IDEALE study (Cotroneo and colleagues) on mild vascular cognitive impairment; small trials by the Parisi and Rossetti groups on glaucoma; and the attention studies by McGlade and colleagues in adult women and adolescent males, both funded by the maker of Cognizin. PMIDs are not listed here until each one is individually confirmed on PubMed.